Gilead Sciences (GILD) Initiates Phase 3 Study for novel Coronavirus vaccine

Follow Us on Stocktwits

Gilead Sciences (NASDAQ: GILD) today announced the initiation of two phase 3 clinical studies for the novel Coronavirus. The study aims to evaluate the efficacy of remdesivir in adults diagnosed with COVID-19.

Find winning trades sent to your inbox every week with Trades Ideas !!!

The study will enroll approximately 1,000 patients at medical centers primarily across Asian countries. It will also include other countries with high numbers of diagnosed cases, beginning in March.

The studies will evaluate two dosing durations of remdesivir. One study will randomize 400 patients with severe clinical manifestations of the novel Coronavirus to receive five or 10 days of remdesivir. The second study will randomize 600 patients with moderate clinical manifestations of disease to receive five or 10 days of remdesivir. The primary endpoint of both studies is clinical improvement, as described below.

Gilead Sciences’ (GILD) CMO, Merdad Parsey said in a statement: “Gilead’s focus is on rapidly determining the safety and efficacy of remdesivir as a potential treatment for COVID-19. These studies help give us a more expansive breadth of data globally on the drug’s profile in a short amount of time”

The Remdesivir drug in not yet liscensed, nor approved by the FDA (Federal Drug Administration). Gilead Sciences is working with government agencies, NGO’s and other local agencies to find a cure for the novel Coronavirus (COVID_19).

Find winning trades sent to your inbox every week with Trades Ideas !!!

For more information,

Visit Gilead Sciences

Be the first to comment

Leave a Reply

Your email address will not be published.


*